Warns against

Vinay Prasad on Approving Drugs After Failed Trials: warns against

What Prasad says

Dr. Vinay Prasad warns against approving drugs whose pivotal trials failed. Of Sarepta’s Elevidys, he says former CBER director Peter Marks “overruled 3 review teams and pushed this product on the market despite a failed trial,” calling the approval “one of the most costly drugs throughout history.” The statement comes from his 2024 letter co-authored with TimothΓ©e Olivier, reported by Pharmaceutical Technology.

His stated reasoning

Prasad’s stated reasoning is that when regulators override their own review teams to approve a product after a failed trial, the evidence standard collapses and patients are exposed to $3.2-million-per-dose therapies with unproven benefit. His later actions at FDA β€” halting Elevidys shipments in July 2025 after patient deaths β€” put this criticism into enforcement practice.

This page chronicles a stated position of the person above. It is not medical advice and not the site's own conclusion.

The Weekly Scoreboard

Every Friday: what the RFK Jr. HHS team did this week — wins, setbacks, warnings — sourced and linked. Free.

One email a week. No spam. Unsubscribe anytime. Β· Follow on Facebook

The Network — One Publisher, Every Front
Published by Bowman Web Services.